The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Loading...
Loading...

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

None of the stocks hit 52-week highs in Monday's session.

Down In The Dumps

(Biotech stocks hitting 52-week lows on Oct. 22)

    Aduro BioTech Inc ADRO(( Merck &, Co., NYSE:MRK)'s not-so-encouraging Phase 1 results for its STING agonist MK-1454 impacted Aduro, which has a similar drug in its pipeline)
  • Advaxis, Inc. ADXS
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Fortress Biotech FBIO
  • Halozyme Therapeutics, Inc. HALO (ESMO presentation)
  • Intermolecular Inc IMI
  • Jounce Therapeutics Inc JNCE (ESMO presentation)
  • KITOV PHARMA LT/S ADR KTOV
  • Kura Oncology Inc KURA (ESMO presentation)
  • Melinta Therapeutics Inc MLNT
  • Mersana Therapeutics Inc MRS
  • Neovasc Inc NVCN
  • Odonate Therapeutics Inc ODT
  • Portola Pharmaceuticals Inc PTLA
  • Provention Bio Inc PRVB
  • Pulse Biosciences Inc PLSE
  • RA Medical Systems Inc RMED
  • SCYNEXIS Inc SCYX
  • Spectrum Pharmaceuticals, Inc. SPPI
  • Trillium Therapeutics Inc TRIL
  • Trinity Biotech plc TRIB
  • Unum Therapeutics Inc UMRX
  • Athenex Inc ATNX(ESMO presentation )
  • Bellicum Pharmaceuticals Inc BLCM
  • BioXcel Therapeutics Inc BTAI
  • bluebird bio Inc BLUE
  • Capricor Therapeutics Inc CAPR
  • Celldex Therapeutics, Inc. CLDX
  • Clovis Oncology Inc CLVS( ESMO presentation)
  • CytomX Therapeutics Inc CTMX (ESMO presentation)
  • CytRx Corporation CYTR
  • Epizyme Inc EPZM (ESMO presentation)
  • Erytech Pharma SA ERYP
  • Exelixis, Inc. EXEL (ESMO presentation)
  • Flexion Therapeutics Inc
  • Stocks In Focus

    Regulus To Present Positive Data For Polycystic Kidney Disease Drug

    Regulus Therapeutics IncRGLS said it would present pre-clinical data for its RGLS4236, a single-stranded, chemically modified oligonucleotide, supporting the clinical development for autosomal dominant polycystic kidney disease, or ADPKD, at the American Society of Nephrology's Kidney Week 2018 meeting.

    The stock jumped 55.74 percent to $2.85 in after-hours trading.

    FSD Pharma to Acquire Therapix

    FSD Pharma Inc FSDDF, a licensed producer of marijuana, announced the signing of a binding letter of intent to buy THERAPIX BIOSCI/S ADR TRPX, which focuses on the development of cannabinoid-based treatments. Therapix shareholders will receive $48 million worth of FSD stock, upon closing of the transaction, representing about 130 million Class B subordinated shares or about 10 percent stake in FSD.

    Therapix stock jumped 58.37 percent to $7 in after-hours trading.

    AbbVie's Ulcerative Colitis Meets Primary & Secondary Endpoints In Mid-stage Study

    AbbVie Inc ABBV reported positive Phase 2b data for its Upadacitinib, showing significant induction of clinical remission and response in patients with ulcerative colitis. The candidate was administered in three doses, namely 15, 30 or 45 mg, as a once daily regimen. It met the primary endpoint of clinical remission per Adapted Mayo Score, and all ranked secondary endpoints.

    Harvard Bioscience Gets a New CFO

    Harvard Bioscience, Inc. HBIO announced the appointment of Kam Unninayanar as its CFO, effective Nov. 26, replacing Robert Gagnon, who resigned from the position, effective August 2018.

    The stock rose 3.49 percent to $4.44 in after-hours trading.

    Common Stock Offerings

    Affimed NV AFMD filed a shelf-registration statement for offering up to $150 million worth of shares, debt securities, warrants, purchase contracts as well as units.

    The stock fell 3.17 percent to $3.05 in after-hours trading.

    Proteostasis Therapeutics Inc PTI announced its intention to offer up to 9 million shares in an underwritten public offering. All the shares are to be sold by the company.

    The stock slumped 11.57 percent to $7.03 in after-hours trading.

    Eiger Biopharmaceuticals Inc EIGR commenced an underwritten public offering of its common stock, with all the shares intended for the offering to be sold by the company.

    The company said it would use the net proceeds to fund its Phase 3 trial of lonafarnib for Hepatitis Delta Virus, lonafarnib's regulatory advancement for treating progeria, and for working capital and other general corporate purposes.

    The stock plunged 13.71 percent to $10.26 in after-hours trading.

    On The Radar

    Earnings

    • Alkermes Plc ALKS Q3 EPS $0.07 Beats $(0.07) Estimate, Sales $248.72M Beat $237.26M Estimate
    • Biogen Inc BIIB Q3 EPS $7.40 Beats $6.80 Estimate, Sales $3.439B Beat $3.33B Estimate
    • Edwards Lifesciences Corp EW(after the market close)
    • Illumina, Inc. ILMN(after the market close)
    • Varian Medical Systems, Inc. VAR(after the market close)

    Clinical Trial Results

    Selecta Biosciences Inc SELB is due to present Phase 2 data for its tophaceous gout candidate SEL-212 at the American College of Rheumatology 2018 Annual meeting.

Loading...
Loading...
Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Posted In: BiotechEarningsNewsOfferingsTop StoriesTrading Ideas
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...